asp5094
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 22, 2016 (NCT02698657)
Timeline
Indications
Studied for
Mechanism of action
- Integrin alpha-9INHIBITOR
ITGA9 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- asp5094
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03257852 | Phase 2 | Sep 29, 2017 | Astellas |
| NCT02698657 | Phase 1 | Feb 22, 2016 | Astellas |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 2 | 2 | 2 | 2016 |
1 organizations
Page 1 / 1